|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
CN102757397A
(zh)
*
|
2005-07-01 |
2012-10-31 |
默沙东公司 |
合成cetp抑制剂的方法
|
|
EP1965764B1
(en)
|
2005-12-05 |
2011-07-13 |
Merck Sharp & Dohme Corp. |
Self-emulsifying formulations of cetp inhibitors
|
|
TW200732313A
(en)
*
|
2005-12-15 |
2007-09-01 |
Astrazeneca Ab |
Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
|
|
JP5192392B2
(ja)
*
|
2005-12-30 |
2013-05-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
コレステリルエステル転送タンパク質阻害剤
|
|
US7915271B2
(en)
|
2005-12-30 |
2011-03-29 |
Merck Sharp & Dohme Corp. |
1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
|
|
EP1973889B1
(en)
*
|
2005-12-30 |
2016-08-24 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors
|
|
EP1971595B1
(en)
*
|
2005-12-30 |
2013-10-16 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors
|
|
JP5773560B2
(ja)
|
2006-02-09 |
2015-09-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｃｅｔｐ阻害剤のポリマー製剤
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
KR101568799B1
(ko)
|
2007-01-26 |
2015-11-12 |
카네크 파마 인코포레이티드 |
융합된 방향족 ｐｔｐ-1ｂ 억제제
|
|
EP2918578A1
(en)
*
|
2007-03-16 |
2015-09-16 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
US8338458B2
(en)
|
2007-05-07 |
2012-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
EP2520561B1
(en)
|
2007-06-08 |
2016-02-10 |
MannKind Corporation |
IRE-1A Inhibitors
|
|
WO2008156717A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
WO2008156718A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
EP2170058B1
(en)
*
|
2007-06-20 |
2013-07-03 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
CN101687844B
(zh)
|
2007-07-02 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
用作ccr2受体拮抗剂的咪唑衍生物
|
|
EP2183228B1
(en)
*
|
2007-07-26 |
2014-08-20 |
Vitae Pharmaceuticals, Inc. |
CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
CA2708303A1
(en)
|
2007-12-11 |
2009-06-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
WO2009094169A1
(en)
*
|
2008-01-24 |
2009-07-30 |
Vitae Pharmaceuticals, Inc. |
Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
CN101952244B
(zh)
*
|
2008-02-01 |
2014-11-05 |
潘米拉制药公司 |
前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
|
|
UA98839C2
(en)
*
|
2008-02-01 |
2012-06-25 |
Панмира Фармасьютикалз, Ллк. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
|
JP5734666B2
(ja)
*
|
2008-02-11 |
2015-06-17 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
|
|
EP2257536A4
(en)
|
2008-02-14 |
2011-03-23 |
Amira Pharmaceuticals Inc |
CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
|
|
US8598160B2
(en)
*
|
2008-02-15 |
2013-12-03 |
Vitae Pharmaceuticals, Inc. |
Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
|
|
JP2011513242A
(ja)
|
2008-02-25 |
2011-04-28 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体アンタゴニスト
|
|
JP5538356B2
(ja)
*
|
2008-03-18 |
2014-07-02 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
|
|
WO2009145989A2
(en)
|
2008-04-02 |
2009-12-03 |
Amira Pharmaceuticals, Inc. |
Aminoalkylphenyl antagonists of prostaglandin d2 receptors
|
|
WO2009134387A1
(en)
|
2008-05-01 |
2009-11-05 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
CL2009001059A1
(es)
|
2008-05-01 |
2010-11-12 |
Boehringer Ingelheim Int |
Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
|
|
AR071236A1
(es)
|
2008-05-01 |
2010-06-02 |
Vitae Pharmaceuticals Inc |
Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
|
|
US8063088B2
(en)
*
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
WO2010011314A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
|
|
CN102105454A
(zh)
|
2008-07-25 |
2011-06-22 |
贝林格尔.英格海姆国际有限公司 |
合成1型11β-羟基类固醇脱氢酶的抑制剂
|
|
US8846668B2
(en)
|
2008-07-25 |
2014-09-30 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
WO2010039977A2
(en)
|
2008-10-01 |
2010-04-08 |
Amira Pharmaceuticals, Inc. |
Heteroaryl antagonists of prostaglandin d2 receptors
|
|
WO2010039474A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone cetp inhibitors
|
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
AU2010206789A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Bridged and fused antidiabetic compounds
|
|
WO2010085525A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
CA2744946A1
(en)
|
2009-02-04 |
2010-08-12 |
Boehringer Ingelheim International Gmbh |
Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
|
UA109255C2
(ru)
|
2009-04-30 |
2015-08-10 |
Берінгер Інгельхайм Інтернешнл Гмбх |
Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
|
|
EP2440537A1
(en)
|
2009-06-11 |
2012-04-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
|
|
WO2011002910A1
(en)
|
2009-07-01 |
2011-01-06 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
CN102596902A
(zh)
|
2009-08-05 |
2012-07-18 |
潘米拉制药公司 |
Dp2拮抗剂及其用途
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
JP5750449B2
(ja)
|
2009-11-05 |
2015-07-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規キラルリンリガンド
|
|
CN102695414A
(zh)
|
2010-01-15 |
2012-09-26 |
默沙东公司 |
作为抗糖尿病化合物的噁二唑β-咔啉衍生物
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US8648192B2
(en)
|
2010-05-26 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
US8933072B2
(en)
|
2010-06-16 |
2015-01-13 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
JP5813106B2
(ja)
|
2010-06-25 |
2015-11-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
|
|
JPWO2012046681A1
(ja)
|
2010-10-04 |
2014-02-24 |
興和株式会社 |
脂質代謝関連ｍＲＮＡの発現抑制剤
|
|
ES2623759T3
(es)
*
|
2010-10-29 |
2017-07-12 |
Merck Sharp & Dohme Corp. |
Oxazolidinonas sustituidas con amina cíclica como inhibidores de CETP
|
|
PH12013500808A1
(en)
|
2010-11-02 |
2015-10-07 |
Boehringer Ingelheim Int |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
EP2468735A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468736A1
(en)
*
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
WO2012101142A1
(en)
|
2011-01-26 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for assessing a subject's risk of having a cardiovascular disease.
|
|
BR112013021236B1
(pt)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
composto derivado de benzimidazol, e, composição
|
|
PL2697207T3
(pl)
|
2011-04-12 |
2017-08-31 |
Chong Kun Dang Pharmaceutical Corp. |
Pochodne 3-(2-arylocykloalkenylometylo)oksazolidyn-2-onu jako inhibitory białka transportującego estry cholesterolu (cetp)
|
|
CN103813789A
(zh)
*
|
2011-07-07 |
2014-05-21 |
持田制药株式会社 |
含有高纯度epa的抗肥胖药
|
|
ES2683350T3
(es)
|
2011-07-08 |
2018-09-26 |
Novartis Ag |
Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
EP2773210A4
(en)
*
|
2011-10-31 |
2015-07-22 |
Merck Sharp & Dohme |
Process for a cetp inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
US20140303198A1
(en)
|
2011-11-29 |
2014-10-09 |
Kowa Company, Ltd. |
Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
|
|
AU2012346755B2
(en)
*
|
2011-11-30 |
2016-09-15 |
Daewoong Pharmaceutical Co., Ltd. |
Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
|
|
WO2013091696A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
EP2844252B1
(en)
*
|
2012-05-02 |
2016-11-30 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic compounds as cetp inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
WO2014012428A1
(zh)
*
|
2012-07-19 |
2014-01-23 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
WO2014031465A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives
|
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
|
EP2934519B1
(en)
|
2012-12-20 |
2021-05-12 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
WO2014119947A1
(en)
|
2013-01-31 |
2014-08-07 |
Chong Kun Dang Pharmaceutical Corp. |
Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
WO2015017302A2
(en)
|
2013-07-30 |
2015-02-05 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
|
|
US9688630B2
(en)
|
2013-10-10 |
2017-06-27 |
Merck Sharp & Dohme Corp. |
3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
CN105814064A
(zh)
|
2013-12-17 |
2016-07-27 |
默沙东公司 |
作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
|
|
WO2015106674A1
(zh)
*
|
2014-01-14 |
2015-07-23 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
WO2016018729A1
(en)
*
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
RU2703192C2
(ru)
|
2014-07-30 |
2019-10-15 |
Ф. Хоффманн-Ля Рош Аг |
Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
CA3029109A1
(en)
|
2016-06-29 |
2018-01-04 |
Orion Corporation |
Benzodioxane derivatives and their pharmaceutical use
|
|
WO2018016743A1
(ko)
*
|
2016-07-19 |
2018-01-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
US10851059B2
(en)
*
|
2016-08-17 |
2020-12-01 |
Novartis Ag |
Processes and intermediates for NEP inhibitor synthesis
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
CA3108437A1
(en)
|
2018-08-09 |
2020-02-13 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|
|
AU2020232350A1
(en)
|
2019-03-07 |
2021-07-29 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for treating or preventing heart failure and reducing risk of heart failure
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
BR112022000963A2
(pt)
|
2019-07-19 |
2022-04-05 |
Biosynth Ag |
Método de fabricação de sais de nicotinamida ribofuranosídeo, sais de nicotinamida ribofuranosídeo como tal e usos dos mesmos
|
|
IL297832A
(en)
|
2020-05-05 |
2023-01-01 |
Nuvalent Inc |
Macrocyclic heteroaromatic chemotherapeutic agents
|
|
KR102698413B1
(ko)
|
2020-05-05 |
2024-08-26 |
뉴베일런트, 아이엔씨. |
헤테로방향족 거대환식 에터 화학치료제
|
|
KR102651062B1
(ko)
*
|
2020-10-08 |
2024-03-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
US20240360103A1
(en)
*
|
2021-06-30 |
2024-10-31 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
IL311444A
(en)
|
2021-10-01 |
2024-05-01 |
Nuvalent Inc |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|